About ProMetic
Management
Pierre Laurin, B.Sc.Pharm., M.Sc.
Chairman of the Board, President & Chief Executive Officer
ProMetic Life Sciences Inc.
Mr. Pierre Laurin has over 25 years of experience in the pharmaceutical and biotechnology industry. Involved in the development of ProMetic's platform technology since 1989, Mr. Laurin founded ProMetic Life Sciences Inc. in 1994. As Chairman and CEO of the Company since its inception, he took the Company public on the Toronto Stock Exchange and has since raised over $95 million through equity financings and multinational funding. Mr. Laurin’s corporate development achievements include the successful close of some 20 licensing agreements and joint venture agreements with multinationals including the American Red Cross, Merck, and Arriva Pharmaceuticals.
Mr. Laurin’s prior experience also includes positions with various pharmaceutical companies, including Nordic Laboratories (now Sanofi-Aventis) where he played a pivotal role in the commercial success of Cardizem, Canada.
Mr. Laurin holds a B.Sc. in Pharmacy and a Masters degree in Pharmaceutical Sciences from the University of Montreal.
Bruce Pritchard, BA, CA, MloD
Chief Financial Officer
ProMetic Life Sciences Inc.
Prior to his nomination as Chief Financial Officer of the ProMetic Group, Mr. Bruce Pritchard was formerly Chief Financial Officer of the U.K. affiliate ProMetic BioSciences Ltd (PBL). Mr.Pritchard is a Chartered Accountant with many years of experience in corporate accountancy including senior finance positions with biotech and pharmaceutical companies. Mr Pritchard has a proven track record of success in strategic acquisitions and raising finance from public and private sources. Mr.Pritchard is currently Chairman of the Institute of Chartered Accountants of Scotland’s England & Wales Area Committee and is a Trustee and Non-Executive Director of The Scottish Global Health Foundation.
Mr.Pritchard is a graduate of Heriot-Watt University where he gained a BA in Accountancy and Computer Science in 1993. He qualified as a Member of the Institute of Chartered Accountants of Scotland in 1996.
Patrick Sartore, B.Sc., LLB.
Senior Legal Counsel, IP &
Corporate Secretary
ProMetic Life Sciences Inc.
Mr. Patrick Sartore joined ProMetic in 2006 as Senior Legal Counsel – Intellectual Property and has since been nominated as Corporate Secretary of the Company. Mr. Sartore was previously employed by Univalor Inc. as Legal Counsel and Leger Robic Richard, L.L.P., a firm specializing in Intellectual Property, Corporate and Commercial Law, as an Associate Attorney. Mr. Sartore has extensive experience in the areas of Intellectual Property (prosecution and management of Patent and Trademark portfolios), Technology Transfer (Licencing Agreements, Material Transfer Agreements and Research and Development Contracts), private and public financing (Venture Capital, Institutional, Debt, Equity) as well as general corporate and commercial law. Mr. Sartore graduated from the University of Montreal with a Bachelor of Law (LLB) in 1999 and was called to the Bar of Quebec in 2001. Mr. Sartore also holds a Bachelor of Science, with Distinction, from Concordia University and is currently completing his Masters degree in taxation at the HEC Montreal. Mr. Sartore is a member of the Intellectual Property Institute of Canada and the Young Bar Association of Montreal.
Christopher L. Penney, Ph.D.
Chief Scientific Officer, Therapeutics
ProMetic BioSciences Inc.
Dr. Christopher Penney received a B.Sc. with honours in biochemistry in 1972 and a Ph.D. in bioorganic chemistry in 1977, both from McGill University, Montreal. His doctoral thesis was under the direction of Bernard Belleau, the well-known Canadian medicinal chemist whose discoveries included the HIV drug, 3TC. Shortly after, Dr. Penney undertook a one-year postdoctoral fellowship at Yale University, under the Nobel Laureate, Paul Greengard.
Dr. Penney is currently Chief Scientific Officer of the Therapeutics Unit of ProMetic BioSciences Inc. Prior to joining ProMetic in June 2001 as Director of Research, Dr. Penney worked in three Canadian biological/biophamaceutical companies, namely Connaught Laboratories (1980-1984), Agritech Research (1985-1987) and BioChem Pharma (1988-2001). He held various research positions where he gained significant experience in commercial immunology and medicinal chemistry. This expertise is reflected in 35 papers and patents as well as co-authorship of one of the first texts in bioorganic chemistry for undergraduate use. Dr. Penney has taught bioorganic chemistry at McGill University and York University (Toronto).
Steven J. Burton, Ph.D.
Chief Executive Officer
ProMetic BioSciences Ltd
Dr. Steven J. Burton has over 22 years of experience in the development of separation processes and materials for the purification of biopharmaceuticals. He was instrumental in the development of Mimetic Ligands™, many of which are currently used as part of industrial bioseparation processes. Dr. Burton is responsible for the creation of a research and development facility at the University of Cambridge; a leading centre for the development of synthetic affinity ligand products and associated purification processes.
After first joining as Research and Development Manager in 1988, Dr. Burton was appointed to the Board of PBL in 1993. In January 1999, Dr. Burton was appointed Vice-President, Research and Development of ProMetic BioSciences Ltd and In 2003, he was promoted to Executive Vice-President with responsibility for ProMetic’s Enabling Technology Business Unit.
From 1986 to 1988, Dr. Burton was a research scientist at Delta Biotechnology, Ltd. where he was responsible for the development of downstream processes for large-scale purification of recombinant protein therapeutics.